Hospital performance and differences by kidney function in the use of recommended therapies after non-ST-elevation acute coronary syndromes.

Autor: Patel UD, Ou FS, Ohman EM, Gibler WB, Pollack CV Jr, Peterson ED, Roe MT, Patel, Uptal D, Ou, Fang-Shu, Ohman, E Magnus, Gibler, W Brian, Pollack, Charles V Jr, Peterson, Eric D, Roe, Matthew T
Zdroj: American Journal of Kidney Diseases; Mar2009, Vol. 53 Issue 3, p426-437, 12p
Abstrakt: Background: Chronic kidney disease (CKD) is associated with an increased risk of cardiac events and death; however, underuse of guideline-recommended therapies is widespread. The extent to which hospital performance affects the care of patients with CKD and non-ST-segment elevation acute coronary syndromes (NSTE ACSs) is unknown.Study Design: Observational cohort.Setting& Participants: 81,374 patients with NSTE ACSs treated at 327 US hospitals.Predictor: Hospital performance, measured by quartiles of composite adherence to American Heart Association class I guidelines for therapy acutely (aspirin, beta-blockers, clopidogrel, heparin, and glycoprotein IIb/IIIa inhibitors) and at discharge (aspirin, clopidogrel, angiotensin-converting enzyme inhibitors, and lipid-lowering agents) in eligible patients.Outcomes& Measurements: Use of each American Heart Association class I acute and discharge therapy stratified by continuous estimated glomerular filtration rate (eGFR). Multivariable models were adjusted for demographics, clinical factors, and hospital features.Results: Better-performing hospitals had lower prescribing rates for most therapies (5 of 9) with lower levels of kidney function, whereas lower-performing hospitals were more likely to have similar prescribing rates across the eGFR spectrum, suggesting that prescribing patterns at these hospitals were insensitive to differences in eGFR.Limitations: Observational design, selection bias of study cohort.Conclusion: Patients with lower levels of kidney function admitted with NSTE ACSs are less likely to receive evidence-based therapies. Treatment disparities related to CKD are most evident at top-performing hospitals. [ABSTRACT FROM AUTHOR]
Databáze: Supplemental Index